Sealbond Ltd, a reporting person affiliated with CK Life Sciences Int'l., (Holdings) Inc., filed a statement of changes in beneficial ownership with respect to Dogwood Therapeutics, Inc. (NASDAQ:DWTX) on October 27, 2026, disclosing a share acquisition dated October 26, 2026.

Key Highlights

  • Acquisition transaction: Sealbond Ltd acquired 4,098,360 shares of Dogwood Therapeutics common stock on October 26, 2026, at a price of $1.22 per share.
  • Private placement: The shares were acquired pursuant to a Subscription Agreement dated October 19, 2026, between Dogwood Therapeutics, Inc. and Sealbond Limited.
  • Post-transaction ownership: Following the transaction, Sealbond Ltd reported direct beneficial ownership of 25,920,693 shares of common stock.
  • Indirect holdings: An additional 2,842,638 shares are held indirectly by Sealbond through Conjoint Inc., a Delaware corporation and co-reporting person.
  • Board representation: Mr. Yu Ying Choi Alan Abel and Dr. Toh Kean Meng Melvin, both affiliated with CK Life Sciences Int'l., (Holdings) Inc., have been appointed to the board of directors of Dogwood Therapeutics, Inc.
  • Multiple reporting persons: The filing was made jointly by Sealbond Ltd, Conjoint Inc., and CK Life Sciences Int'l., (Holdings) Inc., all sharing an address at 2 Dai Fu Street, Tai Po Industrial Estate, New Territories, Hong Kong.

Sealbond Ltd's Private Placement in Dogwood Therapeutics and CK Life Sciences Affiliation

According to the filing, Sealbond Ltd acquired 4,098,360 shares of Dogwood Therapeutics, Inc. common stock on October 26, 2026, at $1.22 per share. The filing states that the acquisition was made "in a private placement pursuant to a Subscription Agreement dated October 19, 2026 by and between the Issuer and Sealbond Limited." Following this transaction, Sealbond Ltd reported direct beneficial ownership of 25,920,693 shares, with an additional 2,842,638 shares held indirectly through Conjoint Inc.

The filing identifies three reporting persons: Sealbond Ltd, Conjoint Inc., and CK Life Sciences Int'l., (Holdings) Inc. ("CKLS"). The filing discloses a chain of corporate ownership in which Sealbond is a wholly-owned subsidiary of Kamfull Limited, which is in turn a wholly-owned subsidiary of Biotech Strategic Holdings Ltd, itself a wholly-owned subsidiary of CKLS, a company incorporated in the Cayman Islands. Conjoint Inc., a Delaware corporation, is described as a wholly-owned subsidiary of Honglad Limited, which traces through ENSO Resources Limited, also ultimately owned by CKLS. CKLS is a life sciences holding company; both Mr. Yu Ying Choi Alan Abel, its Deputy Chairman, and Dr. Toh Kean Meng Melvin, its Vice President, Chief Scientific Officer, and Executive Director, have been appointed to the board of directors of Dogwood Therapeutics, Inc.

The filing further notes that each of Mr. Yu and Dr. Toh "have been deputized to represent the Reporting Person on the board of directors," and that "by virtue of Mr. Yu and Dr. Toh's representation, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the Reporting Person may be deemed a director by deputization of the Issuer." Each of the three reporting persons is identified in the filing as a Director, 10% Owner, and Other. CKLS disclaimed Section 16 beneficial ownership of the reported securities except to the extent of any pecuniary interest.

What Was Disclosed

Sealbond Ltd, an entity affiliated with CK Life Sciences Int'l., (Holdings) Inc., reported the acquisition of 4,098,360 shares of Dogwood Therapeutics, Inc. common stock at $1.22 per share via private placement, with resulting direct beneficial ownership of 25,920,693 shares, plus 2,842,638 shares held indirectly through Conjoint Inc.